Ricardo Velasco‐Carrillo

Ricardo Velasco‐Carrillo

Auto-generated profile, based on publicly available information

Ricardo Velasco‐Carrillo

Tecnológico Nacional de México/Instituto Tecnológico de Altamira Altamira Tamaulipas Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
BVBENJAMIN VELASCO-BEJARANO
BENJAMIN VELASCO-BEJARANO
RVRicardo Velasco‐Carrillo
Ricardo Velasco‐Carrillo
ECEvangelina Camacho‐Frias
Evangelina Camacho‐Frias
JBJahir Bautista
Jahir Bautista
RLRaquel Lopez-Arellano
Raquel Lopez-Arellano
LRLeonardo Rodríguez
Leonardo Rodríguez
Clenbuterol (Clb) can be present in Mexico often but not all over the world in animal tissues and organs, therefore, potentially is derived from animal sources as well. The aims of this study were to develop and validate a method for detecting traces of clenbuterol in beef sausages. A calibration curve showed linearity in the range of 20–500 pg ml−1. The limit of detection (LOD) and lower limit of quantification (LLOQ) were 5 and 10 pg g−1, respectively. The analyte recovery was from 95.70% to 100.40% with an intraday relative standard deviation (RSD%) of 0.99%–2.10% and an interday RSD% of 0.54%–2.34%, R2 = 0.9998. The methodology developed was applied successfully in 15 samples of beef sausage, and 73.3% of the samples tested contained racemic clenbuterol in concentrations between 30 and 471 pg g−1. The UHPLC–MS/MS method developed combines high sensitivity with good selectivity and short chromatographic run time. Additionally, the enantiomeric analysis of clenbuterol performed in beef sausages showed a 59% for R‐(−)‐Clb and 41% for S‐(+)‐Clb. The presence of clenbuterol in beef sausages could represent a risk of unintentional doping in sport field, because the clenbuterol is a banned substance included in the World Anti‐Doping Agency's (WADA) list of prohibited substances.

14 March 2023 in Drug Testing and Analysis
Verified
Journal Article
Open access
BVBENJAMIN VELASCO-BEJARANO
BENJAMIN VELASCO-BEJARANO
IEIvan M. Espinoza‐Muñoz
Ivan M. Espinoza‐Muñoz
AÁAlan Álvarez‐Sánchez
Alan Álvarez‐Sánchez
AGAnuar Gómez‐Tagle
Anuar Gómez‐Tagle
RVRicardo Velasco‐Carrillo
Ricardo Velasco‐Carrillo
LRLeonardo Rodríguez
Leonardo Rodríguez
Clenbuterol (Clb) (4‐amino‐α‐[(tert‐butylamine) methyl]‐3,5‐dichlorobenzyl alcohol) is a sympathomimetic agent that exhibits β2‐agonist activity. It is applied as a bronchodilatory, tocolytic, and mucolytic agent and is authorized for clinical management in both human and veterinary therapeutics as a racemic mixture. However, its use is strictly prohibited in animals destined for food production in countries in the European Union and in the United States and Mexico, among many others. The R‐(−) enantiomer in clenbuterol stimulates β2‐receptors, whereas the S‐(+) enantiomer blocks the effect of β1‐receptors. The aims of this study were to develop a method for detecting and quantifying Clb and its enantiomeric distribution in several bovine tissues. The UHPLC‐MS/MS method developed to quantify the target compound at trace levels in these tissues combines high sensitivity with good selectivity and short chromatographic run time. The tissue samples tested were found to contain racemic Clb in concentrations of 5–447 pg g−1. The enantiomeric analysis of Clb showed that R‐(−)‐Clb is present at higher concentrations in some tissues, whereas S‐(+)‐Clb was detected in a ratio of 55/45 in the liver and heart tissues.